| Date & Time | 3-5 February, 2027 |
|---|---|
| Location | Leuven, Belgium |
A joint conference of the GET-IN & LifeLUNG EU consortia
The rapid evolution of advanced therapy medicinal products (ATMPs) is transforming the therapeutic landscape, offering unprecedented opportunities to address diseases with high unmet medical needs. Across Europe, progress in gene and cell therapies, RNA-based approaches, and engineered tissues is being driven by increasingly integrated efforts spanning basic research, technology development, manufacturing innovation, and clinical translation.
Coordinated by KU Leuven, this joint conference unites the MSCA Doctoral Networks GET-IN and LifeLUNG with the broader Advanced Therapy Medicinal Product (ATMP) community.
Why Attend?
-
Explore cutting-edge advances: Discover the latest breakthroughs across diverse therapeutic modalities and organ systems, including viral vector technologies and advanced disease models.
-
Master next-gen bioprocessing: Gain insights into precision engineering workflows that integrate multi-omics profiling, data-driven analytics, and AI-enhanced workflows.
-
Shape the Future of ATMPs: Join diverse stakeholders to address shared bottlenecks, highlight emerging opportunities, and accelerate the translation of innovative therapies to patients.
By uniting the GET-IN and LifeLUNG consortia within a broader ATMP ecosystem, this meeting catalyses multidisciplinary collaborations to strengthen Europe’s leadership in developing, evaluating, and deploying next-generation advanced therapies.
